Gossamer Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Gossamer Bio, Inc. (Nasdaq: GOSS) on June 14, 2021, covering events occurring on June 9, 2021, and June 10, 2021. The filing primarily addresses corporate governance matters, including the appointment of a new director and the results of the annual meeting of stockholders held on June 9, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on governance and voting results rather than financial performance.
Material Changes and Governance Events
- Director Appointment: On June 10, 2021, the Board appointed Sandra Milligan, M.D., J.D., as a Class I director. Her term expires at the 2022 annual meeting. Dr. Milligan is considered an independent director.
- Compensation for New Director: Dr. Milligan will receive an annual cash retainer of $40,000 and was granted an option to purchase 47,000 shares of common stock, vesting monthly over three years.
- Annual Meeting Results: The company held its annual meeting on June 9, 2021. Key outcomes included:
- Director Elections: Russell Cox and Renée Galá were re-elected as Class III directors.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Executive Compensation: Stockholders approved the compensation of named executive officers on an advisory basis.
- Vote Frequency: Stockholders recommended an annual frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risks, or contingencies. The document contains no management commentary regarding operational strategy or market conditions.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 47,000 stock options granted to Dr. Milligan.
- Confirm the total number of shares outstanding and the percentage of votes represented by the "For" votes in the director elections.
- Review the full text of the Indemnification Agreement referenced in the filing (Exhibit 10.14 to Form S-1).
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.